Alector Posts $124.6M Q3 Net Income on GSK Deferred Revenue; Cash Runway to 2H 2029
ALEC has more than doubled off its 52-week low of $1.09 on light trading volume (0.4× avg).
Summary
Alector's Q3 profit of $124.6 million is driven by one-time GSK deferred revenue recognition, not operations. Combined with the $100M Genentech upfront and ~$75M offering, cash now funds operations into the second half of 2029.
Key Events · Earnings and Guidance · ALEC
-
Q3 Net Income of $124.6 Million
Net income of $124.6 million, or $1.11 per share, versus a $34.7 million net loss a year ago, on collaboration revenue of $162.9 million versus $3.3 million.
-
Profit Is One-Time GSK Revenue Recognition
The revenue jump comes from recognizing the remaining deferred revenue under the GSK collaboration after the July 6, 2026 termination notice extinguished remaining performance obligations — non-recurring.
-
Cash Runway Extended to 2H 2029
$138.7 million in cash, cash equivalents and investments at September 30, 2026, plus the $100 million Genentech upfront and ~$75 million gross offering proceeds, funds operations into the second half of 2029.
-
Pipeline Milestones Pushed to 2027-2028
AL137 targets first-in-human dosing in Australia no later than April 2027 with a U.S. IND in Q2 2027; AL164 and AL062 target first-in-human studies in Q2 2028.
Analysis · ALEC · Life Sciences
The headline profit is an accounting event, not an operating one. Revenue of $162.9 million versus $3.3 million a year ago comes almost entirely from recognizing the remaining deferred revenue under the GSK collaboration after GSK's July 6, 2026 termination notice extinguished the remaining performance obligations. That revenue is non-recurring and will not repeat. What actually matters is the balance sheet: $138.7 million in cash at September 30, plus the $100 million Genentech upfront received after quarter-end and roughly $75 million in gross offering proceeds, funds operations into the second half of 2029. Against that backdrop the pipeline is now entirely ABC-platform based, with AL137 targeting first-in-human dosing in Australia no later than April 2027 and AL164/AL062 in Q2 2028 — a long gap before the next clinical readout.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALEC was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $309.9M. The 52-week trading range was $1.09 to $2.76. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.